

# ATM mediates pRBfunction to control DNMT1 protein stability and DNA methylation

メタデータ	言語: eng 出版者: 公開日: 2017-10-05 キーワード (Ja): キーワード (En): 作成者: メールアドレス: 所属:
URL	<a href="https://doi.org/10.24517/00027453">https://doi.org/10.24517/00027453</a>

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 International License.



**ATM Mediates pRB Function To Control  
DNMT1 Protein Stability and DNA  
Methylation**

Awad Shamma, Misa Suzuki, Naoyuki Hayashi, Masahiko Kobayashi, Nobunari Sasaki, Takumi Nishiuchi, Yuichiro Doki, Takahiro Okamoto, Susumu Kohno, Hayato Muranaka, Shunsuke Kitajima, Ken-ichi Yamamoto and Chiaki Takahashi

*Mol. Cell. Biol.* 2013, 33(16):3113. DOI:  
10.1128/MCB.01597-12.

Published Ahead of Print 10 June 2013.

---

Updated information and services can be found at:  
<http://mcb.asm.org/content/33/16/3113>

---

**SUPPLEMENTAL MATERIAL**

*These include:*

[Supplemental material](#)

**REFERENCES**

This article cites 42 articles, 18 of which can be accessed free at: <http://mcb.asm.org/content/33/16/3113#ref-list-1>

**CONTENT ALERTS**

Receive: RSS Feeds, eTOCs, free email alerts (when new articles cite this article), [more»](#)

---

---

Information about commercial reprint orders: <http://journals.asm.org/site/misc/reprints.xhtml>  
To subscribe to to another ASM Journal go to: <http://journals.asm.org/site/subscriptions/>

---

# ATM Mediates pRB Function To Control DNMT1 Protein Stability and DNA Methylation

Awad Shamma,<sup>a</sup> Misa Suzuki,<sup>a</sup> Naoyuki Hayashi,<sup>a,b</sup> Masahiko Kobayashi,<sup>b</sup> Nobunari Sasaki,<sup>a</sup> Takumi Nishiuchi,<sup>c</sup> Yuichiro Doki,<sup>d</sup> Takahiro Okamoto,<sup>e</sup> Susumu Kohno,<sup>a</sup> Hayato Muranaka,<sup>a</sup> Shunsuke Kitajima,<sup>a</sup> Ken-ichi Yamamoto,<sup>b</sup> Chiaki Takahashi<sup>a</sup>

Division of Oncology and Molecular Biology<sup>a</sup> and Division of Molecular Pathology,<sup>b</sup> Cancer Research Institute, Kanazawa University, Kanazawa, Ishikawa, Japan; Advanced Science Research Center, Kanazawa University, Kanazawa, Ishikawa, Japan<sup>c</sup>; Department of Gastroenterological Surgery, Osaka University, Graduate School of Medicine, Suita, Osaka, Japan<sup>d</sup>; Department of Endocrine Surgery, Tokyo Women's Medical University, Tokyo, Japan<sup>e</sup>

**The retinoblastoma tumor suppressor gene (*RB*) product has been implicated in epigenetic control of gene expression owing to its ability to physically bind to many chromatin modifiers. However, the biological and clinical significance of this activity was not well elucidated. To address this, we performed genetic and epigenetic analyses in an *Rb*-deficient mouse thyroid C cell tumor model. Here we report that the genetic interaction of *Rb* and *ATM* regulates DNMT1 protein stability and hence controls the DNA methylation status in the promoters of at least the *Ink4a*, *Shc2*, *FoxO6*, and *Noggin* genes. Furthermore, we demonstrate that inactivation of pRB promotes Tip60 (acetyltransferase)-dependent ATM activation; allows activated ATM to physically bind to DNMT1, forming a complex with Tip60 and UHRF1 (E3 ligase); and consequently accelerates DNMT1 ubiquitination driven by Tip60-dependent acetylation. Our results indicate that inactivation of the pRB pathway in coordination with aberration in the DNA damage response deregulates DNMT1 stability, leading to an abnormal DNA methylation pattern and malignant progression.**

The retinoblastoma tumor suppressor gene (*RB*) is prevalently mutated at the initiation of retinoblastoma, osteosarcoma, and small-cell lung cancer. However, in the majority of human cancers, retinoblastoma protein (pRB) inactivation is frequently detected during tumor progression and is implicated in various facets of malignant behaviors (1). This suggests that pRB may possess more functions beyond its well-known roles in the control of the cell cycle and differentiation (2, 3). Previous studies demonstrated the direct interaction of pRB with a number of epigenetic modifiers carrying the LXCXE motif, including DNA methyltransferase 1 (DNMT1) (4, 5). pRB has been suggested to play a certain role in nuclear reprogramming in embryonic stem (ES) cells, induced pluripotent stem (iPS) cells, mouse embryonic fibroblasts (MEFs), as well as tumor cells (6–10). Furthermore, *RB* loss was recently shown to contribute to the progression of human retinoblastoma via epigenetic modifications (11). However, the precise mechanism and target genes of the pRB epigenetic function are still largely unknown.

pRB inactivation induces DNA double-strand breaks (DSBs) via multiple pathways (12–17). The MRN (Mre11, Rad50, and NBS1) sensor complex detects DSBs, rapidly activates ataxia telangiectasia mutated (ATM), and recruits ATM to the site of DSBs. ATM then activates a number of transducers, such as MDC1, 53BP1, and BRCA1, and effector kinases, such as Chk2. These proteins subsequently activate molecules required for DSB repair, including the histone variant H2AX (18–20). Our previous study demonstrated that some components of the DNA damage response (DDR) are activated upon *Rb* loss *in vivo* and *in vitro* (15). We therefore speculated that ATM might mediate pRB functions to regulate the DDR pathway.

C cell (calcitonin-producing cell) tumors developed in *Rb*<sup>+/-</sup> mice are precancerous and display many features of the DDR and cellular senescence. Early-stage *Rb*-deficient C cell tumors exhibited many features of the DDR, including activated ATM, but few features of cellular senescence (15). In contrast, cellular senes-

cence markers were predominant in late-stage *Rb*-deficient C cell tumors, and simultaneous deletion of senescence-inducing genes, such as *Ink4a*, *Arf*, or *Suv39h1*, allowed *Rb*-deficient C cells to directly develop into highly malignant tumors (15). Therefore, we thought further genetic analysis of *Rb*<sup>+/-</sup>-based composite knockout mice (15, 21–23) might enable us to elucidate the mechanism that links DDR signals to cellular senescence *in vivo*. To address this, we initiated the current study by analyzing mice lacking both *Rb* and *ATM*. We then discovered that pRB and ATM coordinately regulate DNA methylation by affecting DNMT1 protein stability.

## MATERIALS AND METHODS

**Mouse strains and genotyping.** *Rb*<sup>+/-</sup> mice (a gift from T. Jacks) (21) that had been backcrossed to the C57BL/6J strain for 5 to 7 generations and inbred were crossed with *Ink4a*<sup>-/-</sup> (a gift from N. Sharpless) (24) or *ATM*<sup>+/-</sup> (a gift from J. McKinnon) (25) mice similarly backcrossed to the C57BL/6J strain for at least 5 generations. The resultant F1 progenies were intercrossed to generate F2 mice. Progenies obtained by intercrossing F2 mice were inbred and used in this study. Mouse genotyping was performed as described previously (21, 24, 25). Animals were handled in accordance with the guidelines of Kanazawa University.

**Retroviruses and plasmids.** pCDNA3-YFP-Flag-ATM and -YFP-Flag-ATM<sup>S1981A</sup> were gifts from David Chen (26). MarXIVfhygro-

Received 27 November 2012 Returned for modification 9 January 2013

Accepted 22 May 2013

Published ahead of print 10 June 2013

Address correspondence to Awad Shamma, shamawad@staff.kanazawa-u.ac.jp, or Chiaki Takahashi, chtakaha@staff.kanazawa-u.ac.jp.

Supplemental material for this article may be found at <http://dx.doi.org/10.1128/MCB.01597-12>.

Copyright © 2013, American Society for Microbiology. All Rights Reserved.

doi:10.1128/MCB.01597-12

hDNMT1 was a gift from E. Hara. pEGFPcl-Tip60 and pOZN-Tip60-Flag-HA (27) were gifts from T. Ikura. pLXSB-RB was described previously (15). pRK5-HA-Ubiquitin-WT (28) was purchased from Ad-gene (Boston, MA). For retrovirus production, EcoPak2 (Clontech) cells were used. Transfection of MEFs or the C cell tumor cell line was performed by using FuGene6 (Roche). MEFs or AC232 cells infected with pBabe-puro or pLXSB vectors were selected with 4  $\mu$ g/ml puromycin or 8  $\mu$ g/ml blasticidin S, respectively, for approximately 36 to 48 h.

**Cell culture.** Primary C cell adenocarcinoma cell lines were derived as described previously (15). MEFs were prepared from embryonic day 10.0 (E10.0) or E12.5 embryos derived by intercrossing  $Rb^{+/-}$ ;  $ATM^{+/-}$  or  $Rb^{+/-}$ ;  $Ink4a^{-/-}$  mice. The 3T3 protocol (3-day transfer, inoculum of  $3 \times 10^5$  cells) assay was performed as described previously (15).

**Antibodies.** For immunohistochemistry, immunofluorescence (IF), immunoblotting, or chromatin immunoprecipitation (ChIP) assays, mouse or rabbit antibodies specific to the following proteins were used: proliferating cell nuclear antigen (PCNA) (catalog no. SC-7907; Santa Cruz), Ki67 (catalog no. AB15580; Abcam),  $\gamma$ H2AX (catalog no. 05-636; Upstate), ATM phosphorylated at serine 1981 ( $ATM^{pS1981}$ ) (catalog no. 200-301-500; Rockland) (for immunohistochemistry), p53<sup>pS15</sup> (catalog no. PC386; Calbiochem), histone H3 trimethylated at lysine 9 (H3K9me3) (catalog no. 07-442; Upstate), heterochromatin protein 1 $\gamma$  (HP1 $\gamma$ ) (catalog no. MAB3450; Chemicon), p16<sup>INK4a</sup> (catalog no. SC-1661), calcitonin (catalog no. SC-20725), carcinoembryonic antigen (CEA) (catalog no. AB33562),  $ATM^{pS1981}$  (catalog no. 200-301-400; Rockland), Suv39H1 (catalog no. AB12405; Abcam), ARF (catalog no. AB80), pRBL2 (catalog no. SC-56178), Chk2<sup>pT68</sup> (catalog no. AB38461), p21 (catalog no. 556430; BD),  $\alpha$ -tubulin (catalog no. CP06; Calbiochem), pRB (catalog no. 554136 [BD], MK-15-3 [MBL], and SC-50), DNMT1 (catalog no. 70-203 [Bioacademia Inc.] and AB13537), ubiquitin (catalog no. 3933, Cell Signaling), acetylated lysine (catalog no. 9441; Cell Signaling), HDAC1 (catalog no. SC-7872), UHRF1 (catalog no. AB57083), Tip60 (catalog no. AB79373), DNMT3b (catalog no. SC-81252), ataxia telangiectasia Rad-3-related protein kinase (ATR) (catalog no. SC-1666328), ATM (catalog no. AB78), hemagglutinin (HA) (catalog no. 3F10; Roche), anti-FLAG (catalog no. F4042; Sigma), histone H3K4me2 (catalog no. AB32356), and histone H3K9me3 (catalog no. AB8898). Staining of genetically unmodified (wild-type) thyroid tissues was performed in our previous work (15) for most of the proteins examined in the current study.

**Tagged proteins.** HA-tagged DNMT1 was constructed by inserting a PCR-amplified fragment of MarXIVfhygro-hDNMT1 into pBabe-puro. pEF-BOS-3HA-ATM, -3HA-ATM-CD (D2870A, kinase dead), -3HA-ATM-BD, -3HA-ATM-ES, -3HA-ATM-KS, -3HA-ATM-PM, and -3HA-ATM-KD were constructed by inserting PCR-amplified or restriction-digested fragments of human ATM (hATM) into pEF-BOS (29). pEF-BOS-FLAG-DNMT1-MS, -FLAG-DNMT1-KS, -3HA-DNMT1-D2, -3HA-DNMT1-D3, -3HA-DNMT1-D4, and -3HA-DNMT1-D5 were constructed by inserting a PCR-amplified fragment of hDNMT1 cDNA into pEF-BOS. Structures of these tagged ATM and DNMT1 fragments are shown in Fig. S8 in the supplemental material.

**Immunohistochemistry.** Paraffin-embedded mouse C cell tumors, human medullary thyroid carcinomas (MTCs), and human esophageal cancers were immunostained as described previously (15).

**Immunofluorescence.** Texas Red-conjugated goat anti-mouse or Alexa Fluor 488-conjugated goat anti-rabbit antibody (catalog no. T862 and A11034, respectively; Molecular Probes) was used as the secondary antibody. DNA was visualized by staining with 4',6-diamino-2-phenylindole (DAPI).

**Immunoblotting.** Whole-cell lysates were prepared in MLB buffer or in acid extraction buffer as described previously (15).

**Cell fractionation.** Collected cells were lysed in solution A (10 mM HEPES [pH 7.9], 10 mM KCl, 1.5 mM MgCl<sub>2</sub>, 0.34 M sucrose, 10% glycerol, 1 mM dithiothreitol, protease and phosphatase inhibitors, and 0.1% Triton X-100). The cytoplasmic fraction (C) was harvested from super-

natants after centrifugation at 1,300 rpm for 5 min. The nuclear pellet was washed once with solution A and lysed in solution B (3 mM EDTA, 0.2 mM EGTA, 1 mM dithiothreitol, and protease and phosphatase inhibitors). The soluble nuclear fraction (N) was obtained from supernatants after centrifugation at 1,700 rpm for 5 min. The chromatin pellet (Ch) was washed twice in solution B, collected by centrifugation at 10,000 rpm for 3 min, and resolved in a loading buffer for SDS-PAGE.

**Immunoprecipitation.** Cell lysates were immunoreacted with specific antibodies and analyzed as described previously (15).

**Colony formation assays.** A colony formation assay was performed as described previously (15).

**RNA interference.** Mission TRC short hairpin RNA (shRNA) target sets for ATM (TRCN0000012643 and TRCN0000012647), CDKN2A (TRCN0000077815 and TRCN0000077816), DNMT1 (TRCN0000225698 and TRCN0000225700), and Tip60 (TRCN0000039302 and TRCN0000039303) and the TurboGFP shRNA control vector (SHC004) were purchased from Sigma-Aldrich.

**DNA methylation analysis.** Genomic DNA sequences retrieved from the Mouse Genome Informatics (MGI) database were searched for CpG islands and specific primers by using the Methyl sequence software provided by Applied Bioscience. Bisulfite modification of DNA was performed by using a Methyl Easy Xceed Rapid DNA bisulfite modification kit (catalog no. ME002; Human Genetic Signature) and amplified by PCR using the bisulfite sequencing-specific primers listed in Table S4 in the supplemental material. The amplified DNA fragment was subcloned into T-Vector pMD20 (catalog no. 3270; TaKaRa Bio). Clones were screened by colony PCR, and plasmid DNA was sequenced by using the KB-3130 sequencer (Applied Biosystems). Bisulfite sequencing data were analyzed by using the Quantification Tool for Methylation Analysis (QUMA) provided by RIKEN (<http://quma.cdb.riken.jp/>). Statistical analysis was performed by using the same program.

**ChIP assay.** A ChIP assay was performed as described previously (15). Briefly, cells were cross-linked with 1% formaldehyde for 10 min at room temperature, and the reaction was terminated with 0.125 M glycine. The cells were then lysed in lysis buffer (catalog no. SC-45000), resuspended in high-salt lysis buffer (catalog no. SC-45001), and sonicated for 5 cycles of 30 s. Five hundred micrograms of protein was then immunoprecipitated with anti-H3K4me2 (catalog no. AB32356), anti-H3K9me3 (catalog no. AB8898), or anti-DNMT1 (catalog no. AB13537) antibodies. The DNA was phenol extracted, and the promoters of genes were amplified by PCR (ChIP). Quantitative PCR (quantitative ChIP) was performed by using Fast SYBR green master mix (Applied Biosystems) with a Light Cycler 480 II instrument (Roche), according to the protocols provided by the manufacturers. The sequences of primers used for these amplifications are indicated in Table S5 in the supplemental material, and their locations on the *Ink4a* promoter region are shown in Fig. S6B in the supplemental material.

**DNMT1 activity assay.** DNMT1 activity was measured by using the DNMT1 direct activity assay kit (catalog no. 52050L; BPS Bioscience), according to the manufacturer's protocol. Briefly, protein lysates were incubated with the reaction mixture for 1 h with rocking at 4°C. The reaction mixture was placed onto a substrate-coated plate, incubated with anti-5-methylcytosine antibody, and then incubated with horseradish peroxidase (HRP)-labeled secondary antibody and HRP chemiluminescent substrate. Chemiluminescence of the samples was immediately measured by using a Fluoroscan Ascent FL instrument (Thermo Electric Corporation).

**Microarray.**  $Rb^{-/-}$ ;  $ATM^{-/-}$  MEFs were transfected using nucleofection (nucleofected) with 0.5  $\mu$ g pBabe-puro plus 5.0  $\mu$ g pCDNA3-YFP-Flag-ATM or an empty vector or infected with lentiviruses expressing shRNAs that target DNMT1 and selected with 4  $\mu$ g/ml puromycin or 8  $\mu$ g/ml blasticidin S for 36 to 48 h. Selected cells were grown for a further 48 h in normal culture medium supplemented with 10% fetal bovine serum (FBS) and harvested on ice, and RNA was extracted by using the RNeasy kit (Qiagen Inc.). The quality of the RNA samples was assessed by using

the RNA 6000 Nano LabChip kit (Bioanalyzer 2100; Agilent Technologies). One-color microarray analysis was performed by using an Agilent mouse whole-genome 4X44k Oligo Microarray (Agilent Technologies), as previously described (30).

**Human tumors.** Tumors from patients with MTCs were surgically removed at the Department of Endocrine Surgery; were diagnosed at the Department of Pathology, Tokyo Women's Medical University; and were analyzed according to the guidelines of Tokyo Women's Medical University. Esophageal squamous cell carcinoma (SCC) tumors were surgically removed at the Department of Gastroenterological Surgery; were diagnosed at the Department of Pathology, Graduate school of Medicine, Osaka University; and were analyzed according to the guidelines of Osaka University. Patients did not receive chemotherapy or radiation preoperatively.

**Comet assay.** A Comet assay reagent kit was purchased from Trevigen (catalog no. 4250-050K), and assays were performed as previously described (15).

**BrdU incorporation.** Bromodeoxyuridine (BrdU) incorporation was measured as described previously (15).

**Bisulfite PCR.** Methylation of the *Ink4a* promoter was evaluated by nested PCR with unmethylation- and methylation-specific primers by using the 5' untranslated region of *Ink4a* (Gene bank accession no. U47018), as previously described (24, 31). Bisulfite modification of DNA was performed by using a MethylEasy DNA bisulfite modification kit (catalog no. ME001; Human Genetic Signature). The sequences of the unmethylation- or methylation-specific PCR primers are listed in Table S2 in the supplemental material.

**RT-PCR.** Total RNA was extracted by using the RNeasy minikit from Qiagen (catalog no. 74104), and reverse transcription-PCR (RT-PCR) was performed by using the TaKaRa RNA PCR kit (catalog no. RR019A). The sequences of specific primers are shown in Table S3 in the supplemental material.

**Microarray data accession number.** The microarray data described in this study have been deposited in the NCBI Gene Expression Omnibus database under accession number GSE47501 (<http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE47501>).

## RESULTS


**ATM status affects p16<sup>Ink4a</sup> in *Rb*-deficient tumors.** *Rb*<sup>+/-</sup> mice develop several types of "*Rb*-deficient" tumors as a consequence of normal allele inactivation in somatic cells (3). We analyzed primary thyroid C cell tumors developed in *Rb*<sup>+/-</sup>; *ATM*<sup>+/+</sup> (average age at examination [AE] ± standard error of the mean [SEM] = 12.5 ± 1.5 months), *Rb*<sup>+/-</sup>; *ATM*<sup>+/-</sup> (AE = 7.1 ± 1.3 months), and *Rb*<sup>+/-</sup>; *ATM*<sup>-/-</sup> (AE = 5.4 ± 1.3 months) mice. C cell tumors were not detected in *Rb*<sup>+/+</sup>; *ATM*<sup>-/-</sup> (AE = 9.4 ± 1.4 months) mice (Fig. 1A). Carcinoembryonic antigen (CEA) and Ki67 were frequently expressed in both *Rb*-deficient *ATM*<sup>+/-</sup> and *Rb*-deficient *ATM*<sup>-/-</sup> tumors but were infrequently expressed in *Rb*-deficient *ATM*<sup>+/+</sup> tumors (Fig. 1A; see also Table S1 in the supplemental material). *Rb*<sup>+/-</sup>; *ATM*<sup>-/-</sup> mice exhibited significantly poorer survival than did *Rb*<sup>+/-</sup>; *ATM*<sup>+/-</sup> mice (Fig. 1C). As we previously reported (15), primary *Rb*-deficient *ATM*<sup>+/+</sup> tumors exhibited frequent expression of DDR markers, including ATM phosphorylated at serine 1981 (ATM<sup>PS1981</sup>), histone variant H2AX phosphorylated at serine 139 (γH2AX), and p53 phosphorylated at serine 15 (p53<sup>PS15</sup>) (see Fig. S1 in the supplemental material). Ataxia telangiectasia Rad-3-related protein kinase (ATR) was frequently expressed in *Rb*-deficient, ATM-deficient tumors, and *Rb*-deficient *ATM*<sup>-/-</sup> tumors showed significant accumulation of γH2AX. ATM heterozygosity reduced the frequency of ATM<sup>PS1981</sup> to <10% (see Fig. S1 in the supplemental material); this may explain the haploid insufficiency of the *ATM* locus in

*Rb*-deficient C cell tumors. Consistent with our previous report, *Rb*-deficient tumors frequently expressed senescence markers, including histone H3 trimethylated at lysine 9 (H3K9me3), heterochromatin protein 1γ (HP1γ), and p16<sup>Ink4a</sup> (Fig. 1B). In contrast to the previously studied *Rb*-deficient *N-ras*<sup>-/-</sup> tumors (15), *Rb*-deficient *ATM*<sup>+/-</sup> or *Rb*-deficient *ATM*<sup>-/-</sup> tumors retained frequent expression of H3K9me3, HP1γ, and p19<sup>Arf</sup>. However, p16<sup>Ink4a</sup> expression was very infrequent in these tumors, in sharp contrast to the frequent DNMT1 expression (Fig. 1B). Because promoter methylation is a common mechanism for *Ink4a* gene inactivation, we suspected that ATM activity might influence the *Ink4a* expression level via regulation of DNMT1.


Human sporadic medullary thyroid carcinomas (MTCs) can be classified into two groups: one with high-level pRB expression and the other with low-level pRB expression (15). A total of 200 cells were randomly selected and evaluated for immunopositive nuclear staining in all tumors, and tumors were classified according to the frequency of immunopositive cells into two groups, with cutoff values of ≥50% for high-level expression and <50% for low-level expression. In the current study, we analyzed 5 cases with high-level and 5 cases with low-level pRB expression. Five out of five cases with low pRB levels showed low expression levels of ATM<sup>PS1981</sup>. Four out of the five cases with low pRB levels showed high DNMT1 expression levels; all four of these cases showed low p16<sup>Ink4a</sup> expression levels (see Fig. S2A to D in the supplemental material). One case with low pRB and exceptionally low DNMT1 levels showed very high p16<sup>Ink4a</sup> expression levels. Because pRB inactivation is frequently detected in esophageal cancers, we also tested this correlation in human esophageal squamous cell carcinomas (SCCs). We then detected 8 out of 10 cases with low pRB expression levels. Six out of the eight cases with low pRB levels showed high ATM<sup>PS1981</sup>, low DNMT1, and high p16<sup>Ink4a</sup> expression levels (see Fig. S2E to G in the supplemental material). Although the ATM activation status varied in these two types of human cancers, the strict correlation of ATM<sup>PS1981</sup>, DNMT1, and p16<sup>Ink4a</sup> in low-level pRB-expressing MTCs and esophageal SCCs supports our hypothesis that ATM status might determine p16<sup>Ink4a</sup> expression via regulation of DNMT1 in the absence of pRB.

**ATM status affects p16<sup>Ink4a</sup> in *Rb*-deficient mouse embryonic fibroblasts.** Biallelic loss of *ATM* shortened the life span of *Rb*<sup>-/-</sup> embryos (average life span, ~E13.5) by approximately 3 days. Therefore, we prepared MEFs of varied *Rb* and *ATM* genotypes from E10.0 embryos. Compared to cells derived from *Rb*-deficient *ATM*<sup>-/-</sup> C cell tumors, *Rb*<sup>-/-</sup>; *ATM*<sup>-/-</sup> MEFs adapted easily to adhesive culture conditions. Thus, we extensively analyzed MEFs. Upon a 3T3 protocol assay, *Rb*<sup>-/-</sup>; *ATM*<sup>-/-</sup> and *Rb*<sup>-/-</sup>; *ATM*<sup>+/-</sup> MEFs achieved infinite proliferation significantly earlier than did *Rb*<sup>-/-</sup> or *ATM*<sup>-/-</sup> MEFs (Fig. 2A). In addition, *Rb*<sup>-/-</sup>; *ATM*<sup>+/-</sup> and *Rb*<sup>-/-</sup>; *ATM*<sup>-/-</sup> MEFs but not *Rb*<sup>-/-</sup> or *ATM*<sup>-/-</sup> MEFs could form colonies when plated at a low cell density (Fig. 2B, left). These signs of immortalization were more evident in *Rb*<sup>-/-</sup>; *ATM*<sup>-/-</sup> than in *Rb*<sup>-/-</sup>; *ATM*<sup>+/-</sup> MEFs (Fig. 2A and B). Consistently, immunoblotting showed a tight correlation between DNMT1 and p16<sup>Ink4a</sup> levels in *Rb*-negative MEFs depending on the ATM status (Fig. 2B).

Both the abundance and activity of ATM (ATM<sup>PS1981</sup>) were markedly increased, and the DNMT1 level was downregulated in *Rb*<sup>-/-</sup> MEFs compared to *Rb*<sup>+/+</sup> cells (Fig. 2C). A previous report, however, indicated that *RB* loss upregulates *DNMT1* tran-



**FIG 1** Analysis of *Rb*-deficient C cell tumors with various *ATM* genotypes. (A) Thyroid tumors developed in mice of the indicated genotypes at the indicated months of age were photographed, and the tissues were then analyzed by hematoxylin-eosin (HE) staining and immunostaining with antibodies to the indicated proteins. The frequency of immunopositive cells per 200 normal thyroid or tumor cells was quantified. Columns show means and SEM. Scale bars, 1 mm in macroscopic and 100  $\mu$ m in microscopic pictures. (B) Serial sections of the same tumors were immunostained with antibodies to the indicated proteins and analyzed as described above for panel A. (C) Survival rate in mice of the indicated genotypes. Data are expressed as percent survival.



**FIG 2** Analysis of *Rb*<sup>-/-</sup> MEFs of various *ATM* genotypes. (A) 3T3 protocol assay of MEFs with the indicated genotypes. MEFs were freshly prepared from embryos of timed pregnant inbred mice and cultivated for 3 passages before the start of the 3T3 assay. The cumulative multiplicity in the representative cultures at the indicated passage number is illustrated in the graph. WT, wild type. (B) Representative results from colony formation assays with MEFs of the indicated genotypes plated at  $1 \times 10^3$  cells per 60-mm dish and cultured for 14 days. (C) Immunoblotting analysis of MEFs of the indicated genotypes with antibodies to the indicated proteins. (D) *Rb*<sup>-/-</sup> MEFs infected with retroviruses expressing the indicated proteins were selected and analyzed by immunoblotting. (E) *Rb*<sup>-/-</sup>; *ATM*<sup>-/-</sup> MEFs infected with lentiviruses expressing shRNAs that target the indicated genes were analyzed by a colony formation assay and immunoblotting with antibodies to the indicated proteins. #1 and #2 indicate independently designed shRNAs targeting DNMT1. (F) *Rb*<sup>+/+</sup> or *Rb*<sup>-/-</sup> MEFs infected with lentiviruses expressing the shRNAs that target the indicated genes were selected and analyzed by immunoblotting. GFP, green fluorescent protein. (G) *Rb*<sup>-/-</sup>; *ATM*<sup>-/-</sup> MEFs transduced with vectors expressing the indicated proteins were selected and analyzed by immunoblotting.

scription by severalfold (32). These findings suggested that the genetic interaction between *Rb* and *ATM* might regulate DNMT1 at the posttranscriptional level.

*Rb* deletion upregulated p16<sup>Ink4a</sup>, p21<sup>Waf1/Cip1</sup>, and Suv39h1 with concomitant increases in the levels of H3K9me3 and HP1 $\gamma$ . Simultaneous deletion of *ATM* remarkably decreased the level of p16<sup>Ink4a</sup> and reciprocally upregulated DNMT1 and proliferating cell nuclear antigen (PCNA) (Fig. 2C). Heterozygous deletion of *ATM* also upregulated DNMT1 to a level slightly lower than that with the homozygous deletion (Fig. 2B, right). Furthermore, *Rb* deletion induced Chk2<sup>P168</sup> and p53<sup>P15</sup>, which was significantly attenuated by the simultaneous deletion of *ATM*. In contrast, *Rb*<sup>-/-</sup>; *ATM*<sup>-/-</sup> MEFs showed marked increases in the levels of  $\gamma$ H2AX, ATR, and Chk1<sup>P345</sup> (Fig. 2C). Introduction of pRB into *Rb*<sup>-/-</sup> MEFs decreased ATM<sup>P1981</sup> and increased DNMT1 levels (Fig. 2D). Depletion of DNMT1 significantly increased p16<sup>Ink4a</sup>

levels in *Rb*<sup>-/-</sup>; *ATM*<sup>-/-</sup> MEFs and eliminated their ability to form colonies when plated at a low density (Fig. 2E). We previously demonstrated that an additional *Ink4a* deletion immortalized *Rb*<sup>-/-</sup> MEFs at early passage (15). All these observations suggest that suppression of the *Ink4a* gene by DNMT1 might be the major mechanism underlying the immortal growth of *Rb*<sup>-/-</sup>; *ATM*<sup>-/-</sup> MEFs.

To assess the role of induced and activated ATM in *Rb*<sup>-/-</sup> MEFs, we depleted ATM from *Rb*<sup>+/+</sup> and *Rb*<sup>-/-</sup> MEFs. ATM depletion in *Rb*<sup>-/-</sup> MEFs reduced Chk2<sup>P168</sup> and p53<sup>P15</sup> levels and induced  $\gamma$ H2AX, consistent with the findings for *Rb*<sup>-/-</sup>; *ATM*<sup>-/-</sup> MEFs. However, Chk1<sup>P345</sup> was also attenuated by ATM depletion, contrary to our observations of *Rb*<sup>-/-</sup>; *ATM*<sup>-/-</sup> MEFs. Importantly, ATM depletion in *Rb*<sup>-/-</sup> MEFs upregulated DNMT1 to a level similar to that seen in *Rb*<sup>-/-</sup>; *ATM*<sup>-/-</sup> MEFs, with reciprocal downregulation of p16<sup>Ink4a</sup>. Interestingly, ATM depletion

from  $Rb^{+/+}$  cells rather slightly increased both DNMT1 and p16<sup>Ink4a</sup> levels (Fig. 2F). These findings strongly indicate that the  $Rb$  status is a critical determinant of the regulatory interaction of ATM, DNMT1, and p16<sup>Ink4a</sup>. Immunofluorescence (IF) analysis and Comet assays of ATM-depleted cells showed results consistent with those obtained by immunoblotting (see Fig. S3A in the supplemental material). In addition, ATM depletion allowed  $Rb^{-/-}$  but not  $Rb^{+/+}$  MEFs to form colonies under low-density plating conditions (see Fig. S3D in the supplemental material). Interestingly, the simultaneous depletion of both ATM and p16<sup>Ink4a</sup> was sufficient to immortalize  $Rb^{+/+}$  MEFs (see Fig. S3E in the supplemental material). These findings suggest that inactivation of the CDKIs-pRB pathway in combination with a deficient DDR is sufficient to immortalize MEFs.

Introduction of ATM into  $Rb^{-/-}$ ;  $ATM^{-/-}$  MEFs recovered the DDR, downregulated DNMT1 but not DNMT3b, and rescued p16<sup>Ink4a</sup> (Fig. 2G). ATM reconstitution significantly suppressed colony formation by  $Rb^{-/-}$ ;  $ATM^{-/-}$  MEFs when cultured at a low density (see Fig. S4A in the supplemental material). On the other hand, the effect of gene transduction on cell proliferation became visible only after day 14 (see Fig. S4B and C in the supplemental material). All our assessments of cellular proteins were done at days 10 to 12 after gene transduction. This suggests that most of the above-mentioned changes preceded the effects on the cell cycle possibly given by ATM. ATM introduced into  $Rb^{-/-}$ ;  $ATM^{-/-}$  MEFs exhibited a high level of phosphorylation and induced DDR activation, which was significantly antagonized by pRB (see Fig. S4D in the supplemental material). A mutant form of ATM in which serine 1981 was changed to alanine (ATM<sup>S1981A</sup>) significantly failed to achieve these functions (see Fig. S4 in the supplemental material). Introduction of ATM or ATM<sup>S1981A</sup> into an  $Rb$ -deficient  $ATM^{-/-}$  C cell adenocarcinoma cell line showed results highly similar to those obtained with  $Rb^{-/-}$ ;  $ATM^{-/-}$  MEFs (see Fig. S5 in the supplemental material). Taken together, these findings suggest that  $Rb$  and ATM cooperatively regulate MEF immortalization by modulating the p16<sup>Ink4a</sup> level via control of DNMT1 abundance.


**ATM regulates the DNA methylation status of the *Ink4a* promoter.** To assess the significance of the reciprocal correlation of DNMT1 and p16<sup>Ink4a</sup>, we examined the methylation status of CpG islands residing in the *Ink4a* promoter by bisulfite sequencing. We observed that  $Rb$  loss significantly decreased DNA methylation in the *Ink4a* promoter region (Fig. 3A and C). Surprisingly, simultaneous ATM deletion induced hypermethylation in the same region of the *Ink4a* promoter (Fig. 3B and C). Introduction of ATM but not ATM<sup>S1981A</sup> into  $Rb^{-/-}$ ;  $ATM^{-/-}$  MEFs carrying *Ink4a* promoter hypermethylation and following cultivation under normal conditions for 10 days remarkably reduced the number of methylated CpG nucleotides in the *Ink4a* promoter (Fig. 3B and C; see also Fig. S6A in the supplemental material). Bisulfite PCR with either unmethylation- or methylation-specific primers showed similar results (see Fig. S7A in the supplemental material). Both treatment with the ATM-specific kinase inhibitor KU-55933 and, more importantly, the introduction of pRB antagonized the ATM function to induce the hypomethylation status of the *Ink4a* promoter (Fig. 3B and C; see also Fig. S6A in the supplemental material). Reintroduction of only pRB into  $Rb^{-/-}$ ;  $ATM^{-/-}$  MEFs caused an insignificant change in the *Ink4a* promoter methylation status (Fig. 3B and C; see also Fig. S6A in the supplemental material). Treatment of  $Rb^{-/-}$ ;  $ATM^{-/-}$  MEFs expressing exoge-

nous ATM and pRB with KU-55933 caused an insignificant increase in the *Ink4a* promoter methylation level compared with the marked increase in the *Ink4a* promoter methylation level induced by ATM kinase inhibition in  $Rb$ -deficient MEFs (Fig. 3B and C; see also Fig. S6A in the supplemental material). We thought that this variability of ATM function reflected different levels of ATM activity because exogenously introduced pRB inhibited ATM activation (ATM<sup>PS1981</sup> and p53<sup>PS15</sup>), increased DNMT1 abundance, and suppressed p16<sup>Ink4a</sup> to levels comparable to those observed in  $Rb$ -deficient MEFs treated with KU-55933. Therefore, further treatment of  $Rb^{-/-}$ ;  $ATM^{-/-}$  MEFs expressing exogenous ATM and pRB with KU-55933 did not cause significant changes in either ATM activation, DNMT1 abundance, or the p16<sup>Ink4a</sup> protein level (Fig. 3D). Interestingly, DNMT1 suppression by specific shRNAs or methyltransferase inhibitors significantly reduced DNA methylation, particularly in the CpG nucleotides closer to the transcription start site of the *Ink4a* gene (Fig. 3C; see also Fig. S6A in the supplemental material).

ATM inhibition in the  $Rb$ -negative context suppressed the *Ink4a* mRNA level (see Fig. S7B in the supplemental material). Chromatin immunoprecipitation (ChIP) indicated that simultaneous deletion of  $Rb$  and ATM significantly enhanced binding of DNMT1 and the bivalent histone mark to the *Ink4a* promoter. However, ATM reconstitution in  $Rb^{-/-}$ ;  $ATM^{-/-}$  MEFs diminished DNMT1 binding, with insignificant changes in the histone mark, particularly in the proximal promoter region (Fig. 3E). The effect of  $Rb$  and ATM statuses on DNMT1 binding to the proximal region of the *Ink4a* promoter was confirmed by quantitative ChIP analysis (Fig. 3F). However, the transcription level of *DNMT1* was insignificantly affected by the ATM status in an  $Rb$ -negative context (see Fig. S7C in the supplemental material). Taken together, these observations imply that activated ATM influences the *Ink4a* promoter methylation status by regulating DNMT1 primarily at the posttranscriptional level, and pRB antagonizes these ATM functions by attenuating its activation.

**Active ATM dictates ubiquitination of DNMT1 in the absence of  $Rb$ .** To further explore the functional relationship between ATM and DNMT1, we introduced ATM or ATM<sup>S1981A</sup> into  $Rb^{-/-}$ ;  $ATM^{-/-}$  MEFs and observed the fate of endogenous DNMT1 by IF. Compared to the vector control, ATM but not ATM<sup>S1981A</sup> significantly reduced the intensity of the DNMT1 signal in the nucleus. In addition, we detected a certain degree of colocalization of exogenous ATM<sup>PS1891</sup> and endogenous DNMT1 in the nucleus. However, the ATM<sup>S1981A</sup> and DNMT1 signals were mutually exclusive in the majority of examined cells (Fig. 4A).


DNMT1 is regulated by ubiquitination-dependent degradation at the proteasome (33, 34). Treatment of the ATM-reconstituted  $Rb^{-/-}$ ;  $ATM^{-/-}$  MEFs with a proteasome inhibitor, MG132, increased the DNMT1 level in the nucleus and enhanced its colocalization with ATM<sup>PS1891</sup> in a time-dependent manner (Fig. 4B). In addition, MG132 treatment of vector-transduced  $Rb^{-/-}$ ;  $ATM^{-/-}$  MEFs did not affect the DNMT1 protein level; however, it did dramatically increase the DNMT1 level in ATM-reconstituted cells. Furthermore, MG132 treatment induced accumulation of acetylated and polyubiquitinated DNMT1 in ATM-reconstituted  $Rb^{-/-}$ ;  $ATM^{-/-}$  MEFs (Fig. 4C, lane 5), indicating that ATM accelerates DNMT1 ubiquitination in the absence of  $Rb$ . Treatment of  $Rb^{-/-}$ ;  $ATM^{-/-}$  MEFs simultaneously with MS275 (HDAC1 inhibitor) and MG132 decreased DNMT1 abundance and enhanced accumulation of the acetylated and



**FIG 3** DNA methylation status of the *Ink4a* promoter region in MEFs of various *Rb* and *ATM* genotypes. (A) Results of bisulfite sequencing of the *Ink4a* promoter region in *Rb*<sup>+/+</sup> or *Rb*<sup>-/-</sup> MEFs. (B) *Rb*<sup>-/-</sup>; *ATM*<sup>-/-</sup> MEFs were transfected with the vectors expressing the indicated proteins, selected, cultured for an additional 10 days, and thereafter treated with the indicated reagent (KU-59333 at 10  $\mu$ M for 7 days) and analyzed. (C) Statistical analysis of the results of bisulfite sequencing of the *Ink4a* promoter region in MEFs of the indicated genotypes that were transfected with the expression vectors or infected with lentiviruses expressing shRNAs that target the indicated genes, selected for 72 h, and treated with the indicated reagents (trichostatin A [TSA] at 2  $\mu$ M for 3 days, KU-59333 at 10  $\mu$ M for 5 days, and 5-Aza-dC at 2  $\mu$ M for 3 days). \*,  $P < 0.01$  by Mann-Whitney test. (D) Immunoblotting analysis of MEFs of the indicated genotypes with antibodies to the indicated proteins. MEFs were transfected with the vectors expressing the indicated proteins, selected, cultured for an additional 10 days, and thereafter treated with the indicated reagent (KU-59333 at 10  $\mu$ M for 5 days) and analyzed. (E) CHIP assay of the *Ink4a* promoter region in MEFs of the indicated genotypes. *Rb*<sup>-/-</sup>; *ATM*<sup>-/-</sup> MEFs were transduced with vectors expressing the indicated proteins, selected, and analyzed for binding of the indicated proteins by PCR with specific primers (see Fig. S6B and Table S5 in the supplemental material). Proximal, middle, and distal regions are relative to the transcription start site (see Fig. S6B in the supplemental material). (F) Quantitative ChIP assay of the *Ink4a* promoter region (positions  $\sim -44$  to  $-149$ ) in MEFs of the indicated genotypes. *Rb*<sup>-/-</sup>; *ATM*<sup>-/-</sup> MEFs were transduced with vectors expressing the indicated proteins, selected, and analyzed for DNMT1 binding by qPCR with specific primers (see Fig. S6B and Table S5 in the supplemental material).

polyubiquitinated forms of DNMT1 (Fig. 4C, lane 3), suggesting that increased acetylation of DNMT1 is sufficient to trigger its ubiquitination. Taken together, these findings suggest that ATM promotes acetylation-driven ubiquitination following degradation of DNMT1 in *Rb*-deficient cells.

Next, we asked whether activated ATM regulates the functions of enzymes involved in regulation of DNMT1 acetylation. The immunoprecipitation assay of lysates from MG132-treated cells with DNMT1-specific antibody indicated that DNMT1 is bound to HDAC1 in vector-transduced *Rb*<sup>-/-</sup>; *ATM*<sup>-/-</sup> MEFs. Intro-




**FIG 4** Effects of pRB and ATM on the DNMT1 degradation complex. (A) IF analysis of the indicated proteins in  $Rb^{-/-}; ATM^{-/-}$  MEFs transduced with vectors expressing the indicated proteins. (B) IF analysis of  $Rb^{-/-}; ATM^{-/-}$  MEFs transduced with vectors expressing the indicated proteins and treated with vehicle (DMSO) or 5  $\mu$ M MG132 for the indicated periods of time. Numbers in parentheses indicate percentages of the representative phenotype that appeared in all analyzed cells. (C) Lysates from  $Rb^{-/-}; ATM^{-/-}$  MEFs transduced with vectors expressing the indicated proteins and treated with the indicated reagents were immunoprecipitated with DNMT1-specific antibody and analyzed by immunoblotting. Concentrations and durations of treatments are as follows: MS275 at 5  $\mu$ M for 48 h, cycloheximide (CHX) at 2.5  $\mu$ g/ml for 12 h, and MG132 at 5  $\mu$ M for 12 h. Ub, ubiquitin (D) Lysates from  $Rb^{-/-}; ATM^{-/-}$  MEFs transduced with vectors expressing the indicated proteins were treated with 5  $\mu$ M MG132 for 12 h, immunoprecipitated with antibodies to DNMT1 or ATM, and analyzed by immunoblotting. (E) Lysates from MEFs of the indicated genotypes arrested in S phase and treated with the indicated reagents were immunoprecipitated (IP) with antibodies to DNMT1 or ATM and analyzed by immunoblotting (IB). Cells were arrested in S phase by a double-thymidine block at 2 mM for 18 h (first block), released for 9 h, and blocked for another 17 h (second block); MG132 was used at 5  $\mu$ M for 12 h; and cross-linking was performed with a 1% formaldehyde solution for

duction of ATM precluded HDAC1 from the DNMT1 complex and instead recruited Tip60 acetyltransferase and UHRF1 E3 ligase (Fig. 4D). However, the introduced ATM<sup>S1981A</sup> largely failed to exhibit this function (Fig. 4D). The immunoprecipitation assay with an ATM-specific antibody provided results consistent with those obtained in the experiments described above (Fig. 4D). In addition, the immunoprecipitation assay of lysates from  $Rb^{-/-}$  MEFs with ATM or DNMT1 antibodies indicated that endogenous ATM is bound to DNMT1, and treatment with MG132 or a formaldehyde cross-linker enhanced their binding. Although the ATM level is lower than that in  $Rb^{-/-}$  MEFs, we so far did not detect endogenous ATM-DNMT1 binding in  $Rb^{+/+}$  MEFs even when treated with MG132 or by formaldehyde cross-linking (Fig. 4E). In addition, the introduction of ATM into  $Rb^{-/-}; ATM^{-/-}$  MEFs upregulated Tip60 and suppressed the HDAC1 protein level; however, pRB antagonized this effect of ATM (Fig. 4F), suggesting that activated ATM controls DNMT1 acetylation even by regulating the abundances of HDAC1 and Tip60. Tip60 was recently shown to destabilize DNMT1 via an acetylation-driven ubiquitination mechanism (35); however, the current study proposes that activated ATM plays a critical role in the assembly of the DNMT1 degradation complex. Tip60 depletion from ATM-reconstituted  $Rb^{-/-}; ATM^{-/-}$  MEFs induced a significant down-regulation of ATM<sup>pS1981</sup> and rescued DNMT1 via suppression of its acetylation (Fig. 4G). In contrast, without ATM, overexpressed Tip60 did not affect either the abundance or acetylation of DNMT1 (Fig. 4H), implying that ATM essentially mediates Tip60-induced DNMT1 acetylation. Furthermore, introduction of pRB into ATM-reconstituted  $Rb^{-/-}; ATM^{-/-}$  MEFs disrupted the ATM-DNMT1-Tip60-UHRF1 (DNMT1 degradation complex) (Fig. 4I). Taken together with our findings that pRb regulates ATM activation (Fig. 2D) and that ATM-mediated Tip60 functions to acetylate DNMT1 (Fig. 4F to H), these observations indicated a key role for pRb in regulating the DNMT1 degradation complex.

We next assessed the direct effects of cell lysates from MEFs with various  $Rb$  and  $ATM$  statuses on the activity of DNMT1 *in vitro*. Cell lysates from  $Rb^{-/-}; ATM^{-/-}$  MEFs increased the DNMT1 activity in a dose-dependent manner, whereas cell lysates from  $Rb^{-/-}; ATM^{+/+}$  MEFs significantly attenuated DNMT1 activity. Lysates from wild-type MEFs showed no significant effects on DNMT1 activity (Fig. 5A), whereas lysates from ATM-reconstituted  $Rb^{-/-}; ATM^{-/-}$  MEFs significantly decreased DNMT1 activity. Finally, lysates from  $Rb^{-/-}; ATM^{-/-}$  MEFs transduced with ATM<sup>S1981A</sup> slightly attenuated DNMT1 activity (Fig. 5B). These findings support the notion that pRb stabilizes DNMT1 by antagonizing ATM activation.

10 min at room temperature and terminated with 0.125 M glycine. (F)  $Rb^{-/-}; ATM^{-/-}$  MEFs were transduced with vectors expressing the indicated proteins, selected with 4  $\mu$ g/ml puromycin and 8  $\mu$ g/ml blasticidin S for 5 days, and analyzed by immunoblotting using antibodies specific to the indicated proteins. (G)  $Rb^{-/-}; ATM^{-/-}$  MEFs transduced with vectors expressing ATM were infected with lentiviruses expressing shRNAs that target the indicated genes, selected, and analyzed by immunoblotting. (H)  $Rb^{-/-}; ATM^{-/-}$  MEFs transduced with vectors expressing the indicated proteins were analyzed by immunoblotting. Ac-K, acetylated lysine. (I) Lysates from  $Rb^{-/-}; ATM^{-/-}$  MEFs transduced with vectors expressing the indicated proteins were treated with 5  $\mu$ M MG132 for 12 h, immunoprecipitated with ATM-specific antibody, and analyzed by immunoblotting.



**FIG 5** Physical interaction between ATM and DNMT1. (A) Measurement of the dose-dependent effects of the lysates from MEFs of the indicated genotypes on DNMT1 enzyme activity. (B) Measurement of the dose-dependent effects of the lysates from *Rb*<sup>-/-</sup>; *ATM*<sup>-/-</sup> MEFs transfected with vectors expressing the indicated proteins on DNMT1 enzyme activity. (C) Cytosolic (C), nuclear (N), or chromatin (Ch) protein fractions from *Rb*<sup>-/-</sup>; *ATM*<sup>-/-</sup> MEFs transfected with vectors expressing the indicated proteins and treated with 5  $\mu$ M MG132 for 12 h were analyzed by immunoblotting. (D) IF analysis with antibodies specific to the indicated proteins in *Rb*<sup>-/-</sup>; *ATM*<sup>-/-</sup> MEFs transfected with vectors expressing the indicated proteins. Scale bars, 20  $\mu$ m. (E) Lysates from *Rb*<sup>-/-</sup>; *ATM*<sup>-/-</sup> MEFs transfected with vectors expressing the indicated proteins (see Fig. S8A in the supplemental material) were untreated or treated with 5  $\mu$ M MG132 for 12 h (indicated in parentheses), immunoprecipitated, and analyzed by immunoblotting. (F) Lysates from cells prepared as described above for panel E were analyzed by immunoblotting with antibodies to the indicated proteins. (G) Lysates from FLAG-ATM-reconstituted *Rb*<sup>-/-</sup>; *ATM*<sup>-/-</sup> MEFs transfected with vectors expressing the indicated proteins (see Fig. S8B in the supplemental material) were treated with 5  $\mu$ M MG132 for 12 h, immunoprecipitated with antibodies specific to the indicated proteins, and analyzed by immunoblotting.

Subcellular fractionation and IF analysis of MG132-treated *Rb*<sup>-/-</sup>; *ATM*<sup>-/-</sup> MEFs indicated that endogenous DNMT1 is localized predominantly in the chromatin fraction in vector-transduced *Rb*<sup>-/-</sup>; *ATM*<sup>-/-</sup> MEFs, while introduction of ATM signif-


icantly reduced the abundance of DNMT1 in the chromatin fraction and increased it in the cytosolic fraction, and this was antagonized by the simultaneous introduction of pRB (Fig. 5C and D). In the same setting, pRB reduced the level of exogenous ATM in the chromatin fraction. These findings suggest that the level of insoluble DNMT1 (chromatin fraction) is affected by the status of ATM and pRB, and the localization of ATM to chromatin is dynamically controlled by pRB.

**The ATM kinase domain interacts with the DNMT1 catalytic domain.** To further characterize the physical interaction between ATM and DNMT1, we generated various HA-tagged ATM fragments (see Fig. S8A in the supplemental material) and HA- or FLAG-tagged DNMT1 fragments (see Fig. S8B) and examined their interactions when introduced into *Rb*<sup>-/-</sup>; *ATM*<sup>-/-</sup> MEFs. We found that ATM fragments containing the kinase domain were able to bind to and trigger acetylation and degradation of endogenous DNMT1 when introduced into *Rb*<sup>-/-</sup>; *ATM*<sup>-/-</sup> MEFs (Fig. 5E). Consistent with this, these ATM fragments were able to activate downstream targets, including Chk2 and p53, when overexpressed (Fig. 5F). Furthermore, DNMT1 fragments containing the catalytic domain were able to bind to exogenous ATM when both were introduced into *Rb*<sup>-/-</sup>; *ATM*<sup>-/-</sup> MEFs (Fig. 5G). In summary, these findings indicate that the region in the ATM kinase domain (positions 2740 to 3056) and the region in the DNMT1 catalytic domain (positions 1504 to 1632) are necessary for ATM-DNMT1 binding.

**The pRB-ATM-DNMT1 pathway regulates DNA methylation status.** We next surveyed for genes possibly regulated by the pRB-ATM-DNMT1 pathway. We performed microarray analysis of *Rb*<sup>-/-</sup>; *ATM*<sup>-/-</sup> MEFs to identify genes that simultaneously fit two criteria, i.e., (i) being repressed by endogenous DNMT1 and (ii) being upregulated by exogenous ATM, conceivably through DNMT1 inactivation. We identified 318 genes commonly upregulated in 2 combinations of experiments (cutoff point = 2.0 $\times$ ), namely, *Rb*<sup>-/-</sup>; *ATM*<sup>-/-</sup> MEFs depleted for DNMT1 versus the control and those reconstituted with ATM versus the control (Fig. 6A; see also Table S6 in the supplemental material). Of these genes, we focused on 3 cancer-related genes, *Shc2*, *FoxO6*, and *Noggin*. The frequency of methylated CpG nucleotides in the promoter regions of these genes was invariably high in *Rb*<sup>-/-</sup>; *ATM*<sup>-/-</sup> MEFs (Fig. 6B to G). Importantly, reintroduction of ATM into *Rb*<sup>-/-</sup>; *ATM*<sup>-/-</sup> MEFs markedly reduced the frequency of methylated CpGs in the promoter regions of these genes after 10 days of cultivation under normal conditions. Furthermore, additional introduction of pRB antagonized the ATM-induced suppression of CpG island methylation of the promoter regions of these genes (Fig. 6B to G; see also Fig. S9 in the supplemental material). Taken together, these findings suggest that in the *Rb*-negative context, the ATM-DNMT1 interaction regulates the DNA methylation status of gene promoters.

## DISCUSSION

The current study revealed at least a part of the mechanism that links the DDR to cellular senescence in the *Rb*-deficient context and also a previously unexpected role of the genetic interaction between *Rb* and *ATM* in controlling DNMT1 protein stability (Fig. 7). pRB has been linked to the ATM activation status via DSB formation (13). Our current study proposed additional mechanisms including control of Tip60-dependent ATM autophosphorylation and recruitment of ATM to chromatin. We further




**FIG 6** Genome-wide survey for genes epigenetically regulated by the pRB-ATM-DNMT1 nexus. (A) Venn diagram of microarray analysis. *Rb*<sup>-/-</sup>; *ATM*<sup>-/-</sup> MEFs were transduced with vectors expressing the indicated proteins or infected with lentiviruses expressing the shRNAs that target the indicated genes, selected with 4  $\mu$ g/ml puromycin or 8  $\mu$ g/ml blasticidin S for 72 h, cultured for an additional 4 days under normal culture conditions, and analyzed by microarray analysis. Commonly upregulated genes in the 2 combinations of experiments are shown in red. A list of genes and their ontology are indicated in Table S6 in the supplemental material. (B and C) Results of bisulfite sequencing of the *Shc2* promoter region in MEFs of the indicated genotypes transduced with vectors expressing the indicated proteins and their statistical analysis. (D and E) Results of bisulfite sequencing of the *FoxO6* promoter region in MEFs of the indicated genotypes transduced with vectors expressing the indicated proteins and their statistical analysis. (F and G) Results of bisulfite sequencing of the *Noggin* promoter region in *Rb*<sup>-/-</sup>; *ATM*<sup>-/-</sup> MEFs transduced with vectors expressing the indicated proteins and their statistical analysis. A detailed statistical analysis of the effects of pRB and ATM on the frequency and location of methylated CpG (Me-CpG) nucleotides in the promoters of these three representative genes is shown in Fig. S9 in the supplemental material.

demonstrated that activated ATM physically binds to DNMT1 in a complex with Tip60 and UHRF1 and promotes the acetylation-driven ubiquitination of DNMT1. Recently, Du et al. reported a similar regulation of DNMT1 ubiquitination by Tip60 (35). We demonstrated here that Tip60 requires the presence of ATM to initiate DNMT1 acetylation and following ubiquitination. In addition, Tip60 is also known to acetylate ATM<sup>K3016</sup> that further induces ATM autophosphorylation at multiple sites, including ATM<sup>S1981</sup>, which is required for DDR activation (35, 36) and DNMT1 degradation (observed in this study). Therefore, there is

a possibility that Tip60 regulates both ATM and DNMT1 in the same complex (Fig. 7). Our data also indicate that the unavailability of pRB disables HDAC-mediated protection and promotes the Tip60-mediated inhibition of DNMT1 via ATM modifications (Fig. 7).

The current study indicated that the high level of DNMT1 in cells lacking both *Rb* and *ATM* is a rate-limiting step in maintaining the high level of DNA methylation in several cancer-related gene promoters, including *Ink4a*. A previous report, using a somatic knockout of DNMT1 in HCT116 cell clones, showed an



**FIG 7** Model for the functional interaction of ATM and DNMT1 in the absence of pRB. The molecular species participating in the DNMT1 protein stability regulation complex are dynamically altered depending on the status of pRB and ATM, and these changes actively modulate the DNA methylation status of target gene promoters. DKO, double knockout; AC, acetylation.

insignificant difference in the *INK4a* promoter methylation status between *DNMT1*<sup>+/+</sup> and *DNMT1*<sup>-/-</sup> cells (37). Previous work by the same group indicated that DNMT3B, which was unaffected by pRB or ATM in our *Rb*<sup>-/-</sup>; *ATM*<sup>-/-</sup> cells (Fig. 2G), is functionally redundant with DNMT1 in maintaining the methylation status of the *INK4a* promoter (38). Fournel et al. also demonstrated with another cell line that DNMT1 downregulation was sufficient to reduce the DNA methylation of the *INK4a* promoter (39). In addition, Robert et al. demonstrated that DNMT1 inhibition is a major mechanism by which 5-aza-2'-deoxycytidine (5-AzaC) reactivates the *INK4a* promoter (40). Taken together, these findings indicate that the role of DNMT1 can be rate limiting in the regulation of at least the *Ink4a* promoter methylation status and that this might depend on the cellular context and functional redundancy with other DNA methyltransferases.

DDR activation has been demonstrated to contribute to oncogene-induced senescence (OIS) (41); however, the mechanism linking the DDR to cellular senescence was not known. Most oncogenic signals merge upon the transcriptional upregulation of D-type cyclins, which, in cooperation with CDK4/6, inactivate pRB by initiating its phosphorylation. Thus, we suspect that pRB inactivation and the consequent ATM activation might be a common mechanism of various types of OIS.

Furthermore, our data indicated a possibility that both pRB and ATM are simultaneously inactivated with reciprocal upregulation of DNMT1 in half of sporadic human MTC cases. A previous study demonstrated simultaneous mutations of *RB* and *ATM* in lung adenocarcinomas (42). These observations suggest that the pRB-ATM-DNMT1 nexus might be frequently deregulated in human cancers. Even without mutations in *RB* and *ATM*, a variety of oncogenic signals can affect the activation statuses of both pRB and ATM. Furthermore, tumor cells typically exhibit a certain level of DSBs, as depicted, for instance, by positive  $\gamma$ H2AX stain-

ing observed in their nucleus; this might lead to varied levels of ATM activation. Therefore, there is a possibility that a significant portion of cellular information is translated onto epigenetic modifications via the pRB-ATM-DNMT1 nexus. If so, this scenario may provide at least a part of the mechanism of the abnormal DNA methylation pattern prevalently found in human cancers. This expectation may then endow us with an interesting insight into the future rationale for epigenetic therapy of cancers. Finally, it is noteworthy that *Rb* deficiency in mouse embryos showed abnormal stem cell activity in many lineages (3, 10). There is a possibility that pRB controls the epigenetic status during developmental processes through the pRB-ATM-DNMT1 nexus.

#### ACKNOWLEDGMENTS

We thank J. McKinnon, A. Hirao, T. Jacks, N. Sharpless, D. Chen, E. Hara, and T. Ikura for providing materials; M. Asano and E. Kamimura for support in animal experiments; M. Ewen, D. Peeper, and M. Monden for encouragement; Y. Kido for technical and N. Nagatani for secretarial assistance; and all the colleagues in the Takahashi laboratory for valuable discussion.

This work was supported by the Funding Program for Next Generation World-Leading Researchers (NEXT) to C.T., a grant-in-aid for scientific research (MEXT) to C.T. and A.S., the Astellas Foundation for Research on Metabolic Disorders, the Takeda Science Foundation, the Naito Foundation, the Daiichi-Sankyo Foundation for Life Science, the NOVARTIS Foundation (Japan) for the Promotion of Science, and the Hokkoku Foundation for Cancer Research to C.T.

We declare that we have no conflicts of interest.

#### REFERENCES

- Burkhardt DL, Sage J. 2008. Cellular mechanisms of tumour suppression by the retinoblastoma gene. *Nat. Rev. Cancer* 8:671–682.
- Viatour P, Sage J. 2011. Newly identified aspects of tumor suppression by RB. *Dis. Model. Mech.* 4:581–585.
- Takahashi C, Sasaki N, Kitajima S. 2012. Twists in views on RB functions

- in cellular signaling, metabolism and stem cells. *Cancer Sci.* 103:1182–1188.
4. Robertson KD, Ait-Si-Ali S, Yokochi T, Wade PA, Jones PL, Wolffe AP. 2000. DNMT1 forms a complex with Rb, E2F1 and HDAC1 and represses transcription from E2F-responsive promoters. *Nat. Genet.* 25:338–342.
  5. Dick FA. 2007. Structure-function analysis of the retinoblastoma tumor suppressor protein—is the whole a sum of its parts? *Cell Div.* 2:26. doi:10.1186/1747-1028-2-26.
  6. Lin W, Cao J, Liu J, Beshiri ML, Fujiwara Y, Francis J, Cherniack AD, Geisen C, Blair LP, Zou MR, Shen X, Kawamori D, Liu Z, Grisanzio C, Watanabe H, Minamishima YA, Zhang Q, Kulkarni RN, Signoretti S, Rodig SJ, Bronson RT, Orkin SH, Tuck DP, Benevolenskaya EV, Meyerson M, Kaelin WG, Jr, Yan Q. 2011. Loss of the retinoblastoma binding protein 2 (RBP2) histone demethylase suppresses tumorigenesis in mice lacking Rb1 or Men1. *Proc. Natl. Acad. Sci. U. S. A.* 108:13379–13386.
  7. Lopez-Bigas N, Kisiel AT, DeWaal DC, Holmes KB, Volkert TL, Love J, Murray HL, Young RA, Benevolenskaya EV. 2008. Genome-wide analysis of the H3K4 histone demethylase RBP2 reveals a transcriptional program controlling differentiation. *Mol. Cell* 31:520–530.
  8. Li F, He Z, Shen J, Huang Q, Li W, Lui X, He Y, Wolf F, Li CY. 2010. Apoptotic caspases regulate induction of iPSCs from human fibroblasts. *Cell Stem Cell* 7:508–520.
  9. Liu Y, Clem B, Zuba-Surma EK, El-Naggar S, Telang S, Jensen AB, Wang Y, Shao H, Ratajczak MZ, Chesney J, Dean DC. 2009. Mouse fibroblasts lacking Rb1 function form spheres and undergo reprogramming to a cancer stem cell phenotype. *Cell Stem Cell* 4:336–347.
  10. Sage J. 2012. The retinoblastoma tumor suppressor and stem cell biology. *Genes Dev.* 26:1409–1420.
  11. Zhang J, Benavente CA, McEvoy J, Flores-Otero J, Ding L, Chen X, Ulyanov A, Wu G, Wilson M, Wang J, Brennan R, Rusch M, Manning AL, Ma J, Easton J, Shurtleff S, Mullighan C, Pounds S, Mukatira S, Gupta P, Neale G, Zhao D, Lu C, Fulton RS, Fulton LL, Hong X, Dooling DJ, Ochoa K, Naeve C, Dyson NJ, Mardis ER, Bahrami A, Ellison D, Wilson RK, Downing JR, Dyer MA. 2012. A novel retinoblastoma therapy from genomic and epigenetic analyses. *Nature* 481:329–334.
  12. Duensing S, Munger K. 2002. The human papillomavirus type 16 E6 and E7 oncoproteins independently induce numerical and structural chromosome instability. *Cancer Res.* 62:7075–7082.
  13. Pickering MT, Kowalik TF. 2006. Rb inactivation leads to E2F1-mediated DNA double-strand break accumulation. *Oncogene* 25:746–755.
  14. Frame FM, Rogoff HA, Pickering MT, Cress WD, Kowalik TF. 2006. E2F1 induces MRN foci formation and a cell cycle checkpoint response in human fibroblasts. *Oncogene* 25:3258–3266.
  15. Shamma A, Takegami Y, Miki T, Kitajima S, Noda M, Obara T, Okamoto T, Takahashi C. 2009. Rb regulates DNA damage response and cellular senescence through E2F-dependent suppression of N-ras isoprenylation. *Cancer Cell* 15:255–269.
  16. van Harn T, Fojier F, van Vugt M, Banerjee R, Yang F, Oostra A, Joenje H, te Riele H. 2010. Loss of Rb proteins causes genomic instability in the absence of mitogenic signaling. *Genes Dev.* 24:1377–1388.
  17. Sage J, Straight AF. 2010. RB's original CIN? *Genes Dev.* 24:1329–1333.
  18. Polo SE, Jackson SP. 2011. Dynamics of DNA damage response proteins at DNA breaks: a focus on protein modifications. *Genes Dev.* 25:409–433.
  19. Bensimon A, Aebersold R, Shiloh Y. 2011. Beyond ATM: the protein kinase landscape of the DNA damage response. *FEBS Lett.* 585:1625–1639.
  20. Lukas J, Bartek J. 2009. DNA repair: new tales of an old tail. *Nature* 458:581–583.
  21. Takahashi C, Bronson RT, Socolovsky M, Contreras B, Lee KY, Jacks T, Noda M, Kucherlapati R, Ewen ME. 2003. Rb and N-ras function together to control differentiation in the mouse. *Mol. Cell. Biol.* 23:5256–5268.
  22. Takahashi C, Contreras B, Bronson RT, Loda M, Ewen ME. 2004. Genetic interaction between Rb and K-ras in the control of differentiation and tumor suppression. *Mol. Cell. Biol.* 24:10406–10415.
  23. Takahashi C, Contreras B, Iwanaga T, Takegami Y, Bakker A, Bronson RT, Noda M, Loda M, Hunt JL, Ewen ME. 2006. Nras loss induces metastatic conversion of Rb1-deficient neuroendocrine thyroid tumor. *Nat. Genet.* 38:118–123.
  24. Sharpless NE, Bardeesy N, Lee KH, Carrasco D, Castrillon DH, Aguirre AJ, Wu EA, Horner JW, DePinho RA. 2001. Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis. *Nature* 413:86–91.
  25. Herzog KH, Chong MJ, Kapsetaki M, Morgan JI, McKinnon PJ. 1998. Requirement for Atm in ionizing radiation-induced cell death in the developing central nervous system. *Science* 280:1089–1091.
  26. So S, Davis AJ, Chen DJ. 2009. Autophosphorylation at serine 1981 stabilizes ATM at DNA damage sites. *J. Cell Biol.* 187:977–990.
  27. Ikura T, Ogryzko VV, Grigoriev M, Groisman R, Wang J, Horikoshi M, Scully R, Qin J, Nakatani Y. 2000. Involvement of the TIP60 histone acetylase complex in DNA repair and apoptosis. *Cell* 102:463–473.
  28. Lim KL, Chew KC, Tan JM, Wang C, Chung KK, Zhang Y, Tanaka Y, Smith W, Engelder S, Ross CA, Dawson VL, Dawson TM. 2005. Parkin mediates nonclassical, proteasomal-independent ubiquitination of synphilin-1: implications for Lewy body formation. *J. Neurosci.* 25:2002–2009.
  29. Kobayashi M, Ono H, Mihara K, Tauchi H, Komatsu K, Shibata T, Shimizu H, Uchida K, Yamamoto K. 2006. ATM activation by a sulfhydryl-reactive inflammatory cyclopentenone prostaglandin. *Genes Cells* 11:779–789.
  30. Abe K, Naruse C, Kato T, Nishiuchi T, Saitou M, Asano M. 2011. Loss of heterochromatin protein 1 gamma reduces the number of primordial germ cells via impaired cell cycle progression in mice. *Biol. Reprod.* 85:1013–1024.
  31. Patel AC, Anna CH, Foley JF, Stockton PS, Tyson FL, Barrett JC, Devereux TR. 2000. Hypermethylation of the p16 (Ink4a) promoter in B6C3F1 mouse primary lung adenocarcinomas and mouse lung cell lines. *Carcinogenesis* 21:1691–1700.
  32. McCabe MT, Davis JN, Day ML. 2005. Regulation of DNA methyltransferase 1 by the pRb/E2F1 pathway. *Cancer Res.* 65:3624–3632.
  33. Qin W, Leonhardt H, Pichler G. 2011. Regulation of DNA methyltransferase 1 by interactions and modifications. *Nucleus* 2:392–402.
  34. Bronner C. 2011. Control of DNMT1 abundance in epigenetic inheritance by acetylation, ubiquitination, and the histone code. *Sci. Signal.* 4:pe3. doi:10.1126/scisignal.2001764.
  35. Du Z, Song J, Wang Y, Zhao Y, Guda K, Yang S, Kao HY, Xu Y, Willis J, Markowitz SD, Sedwick D, Ewing RM, Wang Z. 2010. DNMT1 stability is regulated by proteins coordinating deubiquitination and acetylation-driven ubiquitination. *Sci. Signal.* 3:ra80. doi:10.1126/scisignal.2001462.
  36. Sun Y, Jiang X, Price BD. 2010. Tip60: connecting chromatin to DNA damage signaling. *Cell Cycle* 9:930–936.
  37. Rhee I, Jair KW, Yen RW, Lengauer C, Herman JG, Kinzler KW, Vogelstein B, Baylin SB, Schuebel KE. 2000. CpG methylation is maintained in human cancer cells lacking DNMT1. *Nature* 404:1003–1007.
  38. Rhee I, Bachman KE, Park BH, Jair KW, Yen RW, Schuebel KE, Cui H, Feinberg AP, Lengauer C, Kinzler KW, Baylin SB, Vogelstein B. 2002. DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. *Nature* 416:552–556.
  39. Fournel M, Sapieha P, Beaulieu N, Besterman JM, MacLeod AR. 1999. Down-regulation of human DNA-(cytosine-5) methyltransferase induces cell cycle regulators p16ink4A and p21WAF/Cip1 by distinct mechanisms. *J. Biol. Chem.* 274:24250–24256.
  40. Robert MF, Morin S, Beaulieu N, Gauthier F, Chute IC, Barsalou A, MacLeod AR. 2003. DNMT1 is required to maintain CpG methylation and aberrant gene silencing in human cancer cells. *Nat. Genet.* 33:61–65.
  41. Di Micco R, Fumagalli M, Cicalese A, Piccinin S, Gasparini P, Luise C, Schurra C, Garre' M, Nuciforo PG, Bensimon A, Maestro R, Pelicci PG, d'Adda di Fagagna F. 2006. Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. *Nature* 444:638–642.
  42. Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, Cibulskis K, Sougnez C, Greulich H, Muzny DM, Morgan MB, Fulton L, Fulton RS, Zhang Q, Wendl MC, Lawrence MS, Larson DE, Chen K, Dooling DJ, Sabo A, Hawes AC, Shen H, Jiangiani SN, Lewis LR, Hall O, Zhu Y, Mathew T, Ren Y, Yao J, Scherer SE, Clerc K, Metcalf GA, Ng B, Milosavljevic A, Gonzalez-Garay ML, Osborne JR, Meyer R, Shi X, Tang Y, Koboldt DC, Lin L, Abbott R, Miner TL, Pohl C, Fewell G, Haipke C, Schmidt H, Dunford-Shore BH, Kraja A, Crosby SD, Sawyer CS, et al. 2008. Somatic mutations affect key pathways in lung adenocarcinoma. *Nature* 455:1069–1075.